Κυριακή 15 Δεκεμβρίου 2019

Clinical evaluation of botulinum toxin A in the management of temporomandibular myofascial pain

Clinical evaluation of botulinum toxin A in the management of temporomandibular myofascial pain: We did a clinical service evaluation of patient-reported outcomes for pain and change in interincisal distance in patients treated with botulinum toxin A (BTX-A) for temporomandibular myofascial pain at nurse-led clinics. We retrospectively reviewed the clinical records of 100 patients and the prescribing patterns of two OMFS consultants. The mean starting pain score of 7.54 out of 10 was reduced by a mean (SD) of 2.48 (2.1) points after the intervention (p<0.001). The most common prescription was for 100 units (n=59 prescriptions).


Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου